China Antithrombotic Drug Market Discussed in New China Research and Intelligence Report Available at MarketPublishers.com
21 Dec 2012 • by Natalie Aster
LONDON – The worldwide market for antithrombotic drugs is expected to be over USD 24 billion by 2016, with its growth mainly fuelled by Chinese and Indian markets. Currently, the antithrombotic drugs market is relatively small in China. However, it has grown considerably over the last decade. In 2006-2011, for instance, its growth rate was over 18 percent. The local market for hospital-use antithrombotic drugs amounted to around CNY 10 billion in 2012, a rise by approximately 22 percent from 2011. The Chinese market is set to continue witnessing growth in the years ahead. It will possibly be around CNY 19.5 billion by end-2016.
Antithrombotic drugs available in the Chinese market are represented by the following varieties: heparin drugs, lumbrokinase, urokinase, sodium ozagrel and clopidogrel, rivaroxaban, cilostazol, alteplase, propyl gallate, etc.
New study “Research Report on China's Antithrombotic Drug Market, 2013-2017” elaborated by China Research and Intelligence offers a deep insight into the Chinese market for antithrombotic drugs. The report provides all-inclusive overview and analysis of the Chinese antithrombotic drug market. The research study examines major product varieties and price dynamics. Valuable data on the market size, growth rate and possible future development trends of the market can be found in the report.
Research Report on China's Antithrombotic Drug Market, 2013-2017
Published: December, 2012
Price: US$ 2,400.00
More China Market Research Reports by China Research and Intelligence are Available:
- Research Report on China's High-end Medical Treatment Industry, 2013-2017
- Research Report on China's Power Generation Equipment Industry, 2013-2017
- Research Report on China's Automobile Spare Parts Industry, 2013-2017
More insightful market research reports by the publisher can be found at China Research and Intelligence page.